Summary
Introduction
There is emerging evidence that matrix metalloproteinases (MMPs), a large family of calcium-dependent zinc endopeptidases (Birkedal-Hansen et al., 1993) , contribute to the pathogenesis of a number of inflammatory disorders of the CNS (Brosnan et al., 1980; Gijbels et al., 1994; Rosenberg, 
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1995; Matyszak and Perry, 1996; Clements et al., 1997) . However, the expression of MMPs in the PNS and their participation in the pathogenesis of inflammatory demyelinating disorders, such as Guillain-Barré syndrome, has not been explored. We have investigated the levels of expression for MMP mRNA, and the cellular localization of MMP proteins in normal and diseased rat sciatic nerves as a step towards clarifying the possible role of these enzymes in experimental autoimmune neuritis (EAN), an animal model of Guillain-Barré syndrome.
Guillain-Barré syndrome, an acute polyneuropathy, is a heterogeneous disorder which encompasses several clinical subtypes (Thomas, 1992; Hughes, 1995) . In Europe, North America and Australia the most commonly described pathology is acute inflammatory demyelinating polyneuropathy, in which perivascular infiltration by T lymphocytes and macrophage-mediated demyelination are pathological hallmarks (Hartung et al., 1992) . EAN is often used to study mechanisms of acute immune-mediated demyelination in the PNS as it mirrors most of the clinical, electrophysiological and morphological aspects of acute inflammatory demyelinating polyneuropathy (Hartung et al., 1995a, b) .
A pathogenic role for proteinases has been suggested in EAN as treatment with the neutral proteinase inhibitor ε-aminocaproic acid, which was presumed to inhibit plasmin, delayed the onset of symptoms (Schabet et al., 1991) . In addition, intraneural injections of plasmin into rat sciatic nerves produced rapid myelin sheath damage, followed by macrophage recruitment and increased demyelination (Said and Hontebeyrie-Joskowicz, 1992) . Plasmin may be an important physiological activator of pro-MMPs. It can activate pro-stromelysin-1 (Nagase et al., 1990) , which in turn can activate 92 kDa gelatinase in vitro (Okada et al., 1992) . It is not known if MMPs can degrade the peripheral myelin proteins P 0 and P 2 . Initial disruption of the myelin sheath, which may be complement-mediated (Stoll et al., 1991) , would expose the cytoplasmic myelin basic protein (MBP). MMPs can degrade MBP (Chandler et al., 1995) , producing immunogenic fragments which could potentiate the immune response (Opdenakker and Van Damme, 1994) . The direct effect of MMPs on the blood-nerve barrier is not known. Both the blood-nerve barrier and the blood-brain barrier consist of endothelial cells linked by tight junctions and a basement membrane (Wadhwani and Rapoport, 1994) . Injection or induction of MMPs in the brains of rats caused breakdown of the blood-brain barrier (Rosenberg et al., , 1995 Chandler et al., 1997) . Involvement of MMPs in EAN is likely to be multifactorial. MMP activity could cause breakdown of the blood-nerve barrier and facilitate the migration of macrophages and T lymphocytes from the blood to the site of an inflammatory stimulus (Woessner, 1992; Romanic and Madri, 1994; Leppert et al., 1995) .
We recently demonstrated that BB-1101, a combined inhibitor of MMP activity and tumour necrosis factor-alpha (TNF-α) processing, is effective in preventing the development of EAN and can attenuate disease severity when given from symptom onset (Redford et al., 1997) . The beneficial actions of BB-1101 could be mediated either indirectly by inhibiting the MMP-like enzyme which cleaves TNF-α to its mature soluble form (Gearing et al., 1994) , since TNF-α has been implicated in the pathogenesis of EAN , or through the direct inhibition of MMP activity. However, the exact roles of MMPs in the aetiology of EAN have not yet been fully investigated and such information is required to focus the design of MMP-targeted therapies in Guillain-Barré syndrome and other neuroinflammatory disorders.
To assess the levels of expression of MMPs in normal and diseased rat sciatic nerves we used a semiquantitative reverse transcriptase-coupled polymerase chain reaction (RT-PCR), which is a sensitive and accurate method for assaying MMP mRNA (Wells et al., 1996) . Immunohistochemistry was used to show the time course of MMP protein expression and to determine the cellular localization of the proteins.
Material and methods

Induction and clinical assessment of EAN
Adult Lewis rats (n ϭ 30) obtained from Harlan Olac (Bicester, Oxon, UK), weighing 200-250 g at the beginning of the experiment, were used. During the study the rats were housed in cages of two or three animals and allowed access to food and water ad libitum. Animals were cared for and used in strict accordance with The Animals (Scientific Procedures) Act, 1986, under a Home Office licence. On day 0 the rats were anaesthetized using 1.5-2% halothane in oxygen prior to receiving a subcutaneous injection of the peripheral myelin inoculum (0.05 ml) into the right hind foot (n ϭ 21). The emulsion was prepared according to the method of Kadlubowski (Kadlubowski et al., 1980) and contained lyophilized bovine spinal root myelin (2.0 mg) and Mycobacterium tuberculosis (0.5 mg; Difco, Surrey, UK) in Freund's adjuvant (Difco). This regimen has previously been shown to result in 95-100% of the rats developing EAN (Redford et al., 1997) . A control group (n ϭ 9) were given subcutaneous injections of M. tuberculosis (0.5 mg) and Freund's adjuvant only (Difco).
Clinical observation and scoring of disease severity
Animals were weighed and inspected for clinical signs of the disease on a daily basis by an observer blinded to their treatment. A cumulative scoring system was used (Redford et al., 1997) in which the rats received one point for each of the following signs of clinical impairment: 5% weight loss over 2 consecutive days; hunched appearance; decreased tail tip tone; decreased whole tail tone; tail paralysis; decreased toe spreading; sprawling gait; slow righting reflex; no righting reflex; dragging one hind limb; dragging two hind limbs; forelimb weakness; paralysis of one limb; paralysis of two limbs; paralysis of three limbs; and moribund/dead.
In order to follow the development of the disease three rats were killed on each of days 0 (naive), 6, 9, 12, 15, 21 and 28 following the inoculation of peripheral myelin. To control for a non-specific reaction to the injection, three rats which had received adjuvant only were killed on each of days 9, 12 and 15 after the subcutaneous injection. A 4 mm segment was dissected from the right sciatic nerve and positioned in a small volume of Tissue-Tek OCT compound (Lamb, London, UK), and frozen in isopentane cooled on solid CO 2 . The remaining tissue was snap-frozen in liquid nitrogen for extraction of mRNA or for tissue zymography.
Semiquantitative PCR
For preparation of mRNA the tissue was flattened in liquid nitrogen using a stainless steel pestle and mortar. The flattened tissue was then transferred to 2.5 ml of lysis buffer and homogenized for 30 s using an Ultra-turrax T25 (Janke and Kunkel, IKA-Labortechnik). Poly(A) ϩ RNA was isolated from sciatic nerves using a scale-up of the MicroFastTrack® Kit (Invitrogen, Leek, Netherlands) . Approximately 1 µg of the mRNA was used as a template in a cDNA synthesis reaction using a RiboClone cDNA Synthesis System M-MLV (H -) (Promega, Southampton, UK). The protocol used for the quantitative PCR, which relies on a competition reaction in which a synthetic standard cDNA is coamplified with the target cDNA in the same PCR reaction, has been described in detail by Wells (Wells et al., 1996) .
Briefly, synthetic multicompetitor cDNAs, containing tandem arrays of 5Ј and 3Ј priming sites for the MMPs of interest and the two housekeeping genes β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were obtained from British Biotech (Oxford, UK) (Wells et al., 1996) . The synthetic standard PQR6, which contained priming sites for TNF-α and MT-MMP2, was constructed by modification of PQR3 (Wells et al., 1996) using site-directed mutagenesis with primers deleting the stromelysin-1 and collagenase-3 priming sites and replacing them with primer sites for rat TNF-α and MT-MMP2. TNF-α primer pairs used were as follows: forward primer (5Ј-3Ј) CAGATG-GGCTGTACCTTATC and reverse (5Ј-3Ј) TGACTCCAA-AGTAGACCTGC; MT-MMP2 forward (5Ј-3Ј) AACG-AGCGCCTGCGGATG and reverse (5Ј-3Ј) GCATCTG-CACCAGAGCGAA. A known dilution series of the standard multicompetitor cDNAs, PQR2, PQR3 (Wells et al., 1996) or PQR6 was combined with a constant amount of target sciatic nerve cDNA (equivalent to 2 ng of starting mRNA) in the same 50 µl PCR reactions. The reactions contained 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl, pH 9.0, 0.1% Triton X-100, 200 µM of each dNTP, 50 pmol of each primer, 1 unit of Taq DNA polymerase (Promega) and 1 µCi [ 32 P]α-dCTP (Amersham, Buckinghamshire, UK). Cycling conditions were identical for all primer pairs: 35 cycles of 95°C for 30 s, 57°C for 30 s and 72°C for 120 s, then held at 4°C.
Ten microlitres of the PCR reaction was run on precast 6% acrylamide TBE gels (Novex, San Diego, Calif., USA) at 150 V. The bands, which were visualized with ethidium bromide (0.5 µg/ml), were cut out and added to 400 µl of Microscint 40 (Packard, Pangbourne, UK) and the number of counts per minute was determined using a Packard Top Count. The counts were normalized for relative dCTP concentration of the standard and cellular cDNAs. The value of the dilution of standard was plotted on a log-log scale against the ratio of standard cDNA to cellular cDNA. Plotting this ratio we obtained curves with slopes close to 1. The value of the dilution when the ratio of standard to cellular cDNA was equal to 1 was calculated using a curve-fitting program (Delta Graph Professional, Delta Point Inc., Calif., USA) and expressed as a fraction of β-actin or GAPDH. Both β-actin and GAPDH were used as internal standards, the ratio between them remaining constant during EAN (data not shown).
Immunohistochemistry
Transverse (8 µm) and longitudinal (10 µm) sciatic nerve sections were cut on a cryostat (Bright Instruments, Huntingdon, UK) and picked up on gelatinized slides. Sections were fixed for 8 min in absolute alcohol at 4°C (acetone fixation at 4°C was used when the primary antibody was SE 601 and TNF-α) and preadsorbed with 10% normal (goat or horse) serum. The tissue was incubated with the primary antibody for 90 min. Secondary antibodies, [affinitypurified biotinylated anti-rabbit IgG (1 : 200) and rat adsorbed anti-mouse IgG (1 : 100)] were applied to the sections for 45 min (Vector Laboratories, Peterborough, UK). All incubations were performed at room temperature in a humidified chamber. Antibody binding was revealed using the avidin-biotinperoxidase method with diaminobenzidine (DAB) as the chromogen (Hsu and Raine, 1981 ) (Vector Laboratories). Non-specific peroxidase activity was quenched by incubating slides for 20 min in a 1% peroxidase-methanol solution. Control sections were treated in the same way omitting incubation with the primary antibody.
Primary antibodies used in this study to monitor the cellular response included ED-1 at 1 : 300, which recognizes rat macrophages (Dijkstra et al., 1985; Bauer et al., 1994; Damoiseaux et al., 1994) (Serotec, Kidlington, UK); S-100 at 1 : 500, which stains myelinating and non-myelinating Schwann cells (Bhattacharyya et al., 1992) (Sigma, Poole, UK), and OX-19 ascites, a pan T-cell marker (Dallman et al., 1984) , which was kindly provided by the MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, Oxford, UK.
For double-labelling studies with the MMP antibodies and the cellular markers OX-19, ED-1 and S-100, the first primary antibody was revealed as described above. Following development of the DAB chromogen (brown precipitate), the sections were rinsed thoroughly in PBS/0.1% Tween-20 and the second primary antibody was incubated at room temperature overnight. The protocol was followed as above but the chromogen DAB was developed in a nickel peroxidase solution (DAB-Ni), localizing the second antigen with a black precipitate. Controls omitting alternate primary antibodies were performed, and to verify that steric hindrance was not adversely affecting the labelling of the second antigen the order of the primary antibodies was reversed while maintaining the order in which the detection chromogens were used. This resulted in the appropriate reverse-order substrate staining. Table 1 lists the polyclonal antibodies used in this study to identify the MMPs and the peptide sequences against which they were raised (British Biotech). The polyclonal antibodies were raised in rabbit against synthetic peptide sequences, and they detect both the proform and activated form of the MMPs. The antibodies demonstrated no cross-reactivity when tested against a panel of purified MMPs which included 72 kDa gelatinase, 92 kDa gelatinase, stromelysin-1, interstitial collagenase, matrilysin and macrophage metalloelastase, by Western blotting or enzyme-linked immunosorbent assay. The optimal concentration was determined for each antibody. Negative controls, in which the antibody was preabsorbed with the peptide against which it was raised, or with purified MMP, showed no staining.
Antibodies against the MMPs
Antibody against TNF-α
A polyclonal antibody raised against human TNF-α (R&D Systems, Abingdon, UK), was used at a concentration of 1 : 500 on acetone-fixed tissue sections. No immunostaining was detected on sections using the antibody after it was preabsorbed against human TNF-α.
Zymography
The sciatic nerves were flattened in liquid nitrogen using a stainless steel pestle and mortar. The flattened tissue was weighed and homogenized in~500 µl of zymogram lysis buffer [20 mM phosphate-buffered saline, 0.05% Triton X-100 and a cocktail of proteinase inhibitors (Sigma)] for 30 s using an Ultra-turrax T25 (Janke and Kunkel, IKALabortechnik). Protein concentrations were determined with a modified Bradford dye-binding procedure (Bio-Rad protein assay, Bio-Rad, Herts, UK). Precast and prestained 10% polyacrylamide minigels containing 0.1% casein were obtained from Novex. The samples were diluted 1 : 4 with 5ϫ non-reducing loading buffer, 0.4 M Tris-HCl, pH 6.8, 20% glycerol, 5% sodium dodecyl sulphate, 0.1% bromophenol blue. Prior to being loaded the zymograms were pre-run for 30 min to allow excess protein to migrate out of the gel (Fernandez-Resa et al., 1995) . The samples were then run at 200 V for 1 h until the dye front had reached the bottom of the gel. After electrophoresis the gels were washed for 30 min at room temperature in a 2.5% Triton X-100 solution to remove sodium dodecyl sulphate. The gels were then incubated for 72 h at 37°C in developing buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 2.5 mM CaCl 2, 0.02% Brij-35), to allow proteolysis of the casein substrate. To confirm specificity of MMP activity, BB-2116 (10 µM), a broad-spectrum MMP inhibitor (Gearing et al., 1994) , was added to the Triton X-100 solution and the developing buffer. Purified human recombinant matrilysin (50 ng) and stromelysin-1 (250 ng) (Chandler et al., 1995) were used as standards. Prestained Seeblue marker proteins (Novex) were used to estimate molecular weight.
Results
Semiquantitative PCR analysis
We found no significant difference in the mRNA expression of MMPs in the sciatic nerves of naive rats compared with rats which received control subcutaneous injections of M. tuberculosis and Freund's adjuvant only. A preliminary study was carried out comparing MMP expression in the sciatic nerve of control rats with expression in rats in which EAN was induced (21 days after inoculation). A summary of the relative expression of the MMPs expressed as a fraction of β-actin is shown in Fig. 1 . This study revealed that five MMPs were constitutively expressed in the sciatic nerve of control animals, including 72 kDa gelatinase and the membrane-type metalloproteinases MT-MMP1 and MT-MMP2. In comparison, lower expression levels of stromelysin-1 and stromelysin-3 were also detected in control nerves.
In rats which displayed neurological deficits associated with EAN, expression of matrilysin, macrophage metalloelastase and 92 kDa gelatinase was induced. Matrilysin mRNA, which was scarcely detectable in control sciatic nerves (Ͻ2.5 ϫ 10 -5 of β-actin), was upregulated 1000-fold. Similarly, 92 kDa gelatinase and macrophage metalloelastase, which were expressed at low levels in the control nerve, were upregulated 60-and 90-fold, respectively, in EAN nerves. Stromelysin-3 mRNA, which was constitutively expressed in control nerves (1.6 ϫ 10 -3 of β-actin), increased four-fold at day 21 (Fig. 1) . However, at all the other time points examined during EAN there was no significant change in the mRNA expression of stromelysin-3 when compared with control mRNA levels (data not shown). Stromelysin-1 expression in the sciatic nerve was reduced by~25% in EAN rats compared with controls (Fig. 1) . The expression levels of MT-MMP1, MT-MMP2 and 72 kDa gelatinase showed no significant changes at any of the time points examined during EAN, when compared Fig. 1 Summary of MMP mRNA expression in the sciatic nerve of control and EAN (day 21) rats, as determined by semiquantitative RT-PCR. Results are the mean for three animals Ϯ SD and are expressed as a fraction of β-actin. In the sciatic nerve of control animals matrilysin*, 92 kDa gelatinase* and macrophage metalloelastase (MME)* mRNA expression levels were too low to quantify accurately (Ͻ2.5 ϫ 10 -5 the level of β-actin). In both control and EAN rats, collagenase-3 and stromelysin-2 mRNAs were Ͻ2.5 ϫ 10 -5 and are not represented on the graph. with the mRNA expression in control rat sciatic nerves (data not shown). Collagenase-3 and stromelysin-2 were not detected in the sciatic nerve of either control or EAN animals during the course of EAN.
Based on these observations we investigated the time course of expression during EAN of the upregulated MMPs, matrilysin, 92 kDa gelatinase, macrophage metalloelastase and the only downregulated MMP, stromelysin-1. We studied the expression for these four MMPs in the sciatic nerve of animals on days 0, 6, 9, 12, 15, 21 and 28 days after inoculation. The development of EAN over this period was assessed by monitoring the clinical signs, using the scoring system described in Material and methods, and weighing the animals daily ( Fig. 2A and B) . All animals which received the peripheral myelin inoculum developed clinical signs of EAN, with weight loss from approximately day 11 and a mean peak clinical score of 12 (including weakness of both hind limbs) at day 15. A partial recovery in clinical signs was observed in the later stages, such that a mean score of 8 (including sprawling gait) was still present at day 28. The control animals which received M. tuberculosis in Freund's adjuvant only did not develop any clinical signs of EAN.
The expression of 92 kDa gelatinase was elevated early in the course of EAN (day 9), prior to the development of any clinical deficits, and then continued to increase following the course of disease progression. Expression peaked at day 15, when the clinical symptoms were most severe, at 500-fold higher than control levels. During the recovery period, on days 21 and 28, the partial recovery correlated with a reduction in expression levels, although 92 kDa gelatinase mRNA was still significantly upregulated compared with control levels (Fig. 3A) .
No change in matrilysin or macrophage metalloelastase expression level was observed until disease severity reached a maximum at day 15. Unlike 92 kDa gelatinase, matrilysin and macrophage metalloelastase showed levels of mRNA expression that continued to rise for the duration of the disease. However, the maximum increase in matrilysin mRNA was 60-fold greater than the peak level of macrophage metalloelastase expression ( Fig. 3B and C) .
Stromelysin-1 mRNA was constitutively expressed in control rat sciatic nerves (2 ϫ 10 -4 of β-actin). During EAN its expression was elevated as early as day 9, showing a maximum 50-fold increase at day 15. By days 21 and 28 the mRNA levels had fallen sharply, returning to basal expression levels (Fig. 3D) .
We found constitutive expression of TNF-α in control nerves. The mRNA expression of the proinflammatory cytokine was elevated from control levels at only one of the time points we analysed during the course of EAN, corresponding with peak disease severity (Fig. 3E ).
Detection and localization of MMPs and TNF-α by immunohistochemistry
Immunohistochemical analysis was performed on sections from the same sciatic nerves as those used in the PCR time course study to confirm the translation of mRNA into specific protein, and to localize the MMPs.
We have previously reported that 92 kDa gelatinase immunostaining is increased in EAN animals 21 days after inoculation (Redford et al., 1997) . In this more detailed study we detected elevated 92 kDa gelatinase immunoreactivity from as early as day 12, prior to a significant cellular invasion into the nerve, in the endothelial cells of blood vessels and Schwann cells (Fig. 4) . As in our initial study (Redford et al., 1997) , at day 21 after inoculation Schwann cells and endothelial cells remained labelled, and a proportion of the OX-19-positive T lymphocytes cuffing endoneurial vessels also contained 92 kDa gelatinase (Fig. 7C) .
Stromelysin-1 was present in Schwann cells and stained endothelial cells weakly in control tissue (Fig. 4D) . In tissue taken at days 12 and 15 after inoculation, the blood vessels showed strong immunostaining (Fig. 4E) . However, unlike 92 kDa gelatinase staining, at later time points in EAN stromelysin-1 immunoreactivity was reduced. Blood vessels were now only lightly labelled and stromelysin-1 positive Schwann cells were barely detectable (Fig. 4F) .
Using the affinity-purified antibody RP-21, matrilysin was co-localized with the Schwann cell marker S-100 in control sciatic nerves (Fig. 5) . During EAN the number of cells expressing matrilysin protein significantly increased ( Fig. 6A and B). Double labelling identified ED-1-positive macrophages as one of the cellular sources of matrilysin in EAN (Fig. 7D) . ED-1-positive macrophages produced matrilysin throughout the course of the disease, whether infiltrating the sciatic nerve at day 15 or actively phagocytosing the myelin debris in the later stages of the disease (data not shown). In EAN lesions T lymphocytes (OX-19-positive) were identified from day 12 onwards and double labelling revealed that they also contained matrilysin (Fig. 7A) . Schwann cells remained labelled for matrilysin throughout EAN.
Macrophage metalloelastase immunoreactivity was increased from day 15 onward (Fig. 6D) , showing a pattern of staining similar to that of matrilysin, with both macrophages and T lymphocytes in EAN lesions positive for macrophage metalloelastase ( Fig. 7B and E) . Schwann cells were labelled in control nerves (Fig. 6C) .
As previously reported (Wagner and Myers, 1996) , TNF-α immunoreactivity was localized to the Schwann cells in control sciatic nerves. At peak disease severity (day 15) an increase in TNF-α immunostaining was detected (Fig. 8) around endoneurial blood vessels. The TNF-α immunostaining co-localized with ED-1-positive macrophages labelled in consecutive sections (data not shown).
Casein zymography
Casein zymograms have a detection limit at least two orders of magnitude lower than the gelatin zymograms for detecting some MMP activity (Manicourt and Lefebvre, 1993) . Therefore, the zymograms were incubated for 72 h to maximize proteolysis. In addition to the gelatinase activity previously detected (not shown; see Redford et al., 1997) , bands which appeared to correspond to intermediate (~39 and~34 kDa) and activated (27 kDa) forms of stromelysin-1 were identified in control samples (lane 3, Fig. 9 ). In EAN sciatic nerves, 15 and 21 days after inoculation, there was an increase in both the intermediate and activated forms of stromelysin-1 (lanes 4 and 5, Fig. 9 ). Additionally, in the day-21 EAN sample a prominent band at~19 kDa, likely to be the activated form of matrilysin, was present. The activated form of macrophage metalloelastase runs at~18 kDa, and therefore we cannot rule out its presence contributing to the activity detected in the zymogram (Fig. 9) . All the activity shown in the zymogram was inhibited by the addition of BB-2116 to the developing buffer (data not shown).
Discussion
We have investigated the local expression of MMPs during experimental immune-mediated inflammation in the PNS. We have shown that 72 kDa gelatinase, MT-MMP1, MT-MMP2 and stromelysin-3 are expressed constitutively in control rat sciatic nerves, and that their expression levels remain unaltered throughout the course of EAN. However, this observation does not rule out the involvement of these Fig. 4 Representative photomicrographs of transverse sciatic nerve sections (8 µm) immunostained for 92 kDa gelatinase (SE-601) (A-C) and stromelysin-1 (RP-58) (D-F) during EAN. In nerves from controls both MMPs were present in Schwann cells (arrowhead) and lightly stained blood vessels (A and D). At day 12, prior to significant invasion of inflammatory cells into the endoneurium, the immunoreactivity of blood vessels increased for 92 kDa gelatinase (B) and stromelysin-1 (E). At day 28 Schwann cells and cells present in the lumen and cuffing the blood vessels remained densely stained for 92 kDa gelatinase (C). However, stromelysin immunoreactivity at day 28 was reduced and only faintly stained blood vessels and Schwann cells (F).
MMPs in the pathogenesis of EAN, as MMPs are also regulated at the post-transcriptional level. We have previously detected an increase in 72 kDa gelatinase activity in EAN (Redford et al., 1997) ; the latent proform can be activated by other proteinases, such as plasmin (Murphy, 1992) , which has been implicated in the pathogenesis of EAN (Schabet et al., 1991) , or by MT-MMP1 (Sato et al., 1994) , which we have found to be highly expressed in the rat PNS (Fig.  1) . The mRNA levels of four MMPs-matrilysin, 92 kDa gelatinase, stromelysin-1 and macrophage metalloelastaseare elevated during EAN, but they show different profiles of expression and varying cellular localization during the time course of the disease. These observations raise questions as to the specific physiological function of the MMPs during EAN. The potential consequences of elevated levels of MMPs in EAN include damage to the blood-nerve barrier, leucocyte extravasation, elevation of TNF-α, demyelination and the production of antigenic myelin fragments Woessner, 1992; Gijbels et al., 1993; Proost et al., 1993; Gearing et al., 1994; Chandler et al., 1995; Leppert et al., 1995) .
kDa gelatinase and blood-nerve barrier breakdown
In EAN, breakdown of the blood-nerve barrier is one of the earliest morphologically demonstrable events (Powell et al., 1983 (Powell et al., , 1991 , but the exact cellular and molecular mechanisms involved are unknown. The early and sustained elevation of 92 kDa gelatinase mRNA expression (Fig. 3A) , and the increased immunoreactivity around endoneurial blood vessels (Fig. 4) , suggest that 92 kDa gelatinase may participate in the disruption of the blood-nerve barrier. This view receives further support from our own experiments investigating Wallerian degeneration in the PNS (data not shown) and Fig. 5 In the sciatic nerves of control animals, matrilysin was colocalized with S-100, a Schwann cell marker. This representative photomicrograph confirms that matrilysin (brown precipitate) is present in S-100-positive Schwann cells (black precipitate). Macrophage metalloelastase, stromelysin-1 and 92 kDa gelatinase were all localized to Schwann cells in control sciatic nerves using this method (data not shown). from the studies of Gijbels et al. (1994) on experimental autoimmune encephalomyelitis. In this equivalent disorder of the CNS, the reversal of clinical deficits by an MMP inhibitor correlated with restoration of the integrity of the blood-brain barrier and 92 kDa gelatinase activity was detected in the CSF of mice with experimental autoimmune encephalomyelitis (Gijbels et al., 1994) . Upregulation and localization of 92 kDa gelatinase similar to that in EAN, corresponding to the time course of blood-nerve barrier breakdown, is also observed during Wallerian degeneration in the rat PNS (data not shown).
We demonstrated that 92 kDa gelatinase was localized to a proportion of the T lymphocytes found primarily cuffing blood vessels (Fig. 7) . This finding correlated with in vitro studies in which human T lymphocytes produced 92 kDa gelatinase (Zhou et al., 1993; Leppert et al., 1995) . Activated T lymphocytes can cause focal disruption of the blood-nerve barrier (Harvey et al., 1995; Spies et al., 1995) and have been implicated as one cell type responsible for blood-nerve barrier breakdown in EAN (Powell et al., 1991) . In vitro T cell migration across endothelial cells and a basal lamina equivalent was reduced by specific inhibitors of MMPs (Romanic and Madri, 1994; Leppert et al., 1995) , supporting the suggestion that in EAN activated T lymphocytes may be dependent on MMP activity to cross endothelial cells and penetrate the subendothelial basal lamina.
Disruption of the blood-nerve barrier in EAN allows potentially damaging mediators in the serum, such as Fig. 7 Matrilysin and macrophage metalloelastase were co-localized with ED-1-positive macrophages and T cells (OX-19-positive) in EAN lesions. 92 kDa gelatinase was identified in OX-19-positive T lymphocytes. Perivascular T lymphocytes, revealed using DAB-Ni (black) were double-labelled for matrilysin (A), macrophage metalloelastase (B) and 92 kDa gelatinase (C). All MMPs were identified using DAB as the chromogen (orange-brown precipitate). Matrilysin and macrophage metalloelastase immunostaining (brown) was associated with phagocytic, foamy ED-1 positive macrophages (black) (D and E). Bar represents 15 µm for all panels (A-E).
complement and anti-myelin antibodies, access to the endoneurium (Harvey and Pollard, 1992) . EAN serum has been shown to be toxic to myelin in vitro (Raine and Bornstein, 1979) and in vivo (Pollard et al., 1981) and could initiate demyelination, leading to conduction block (Saida et al., 1978) . Microinjections of purified 92 kDa gelatinase are currently being studied in an attempt to confirm the suggested role of the MMP in the breakdown of the bloodnerve barrier.
Leukocyte migration and MMPs
Matrilysin and macrophage metalloelastase expression was too low to quantify accurately in control sciatic nerves, and a significant increase in the level of mRNA expression was not observed until day 15 ( Fig. 3B and C) , corresponding with a pronounced cellular infiltration into the nerve (data not shown). Both macrophages and T lymphocytes invading the endoneurium were positive for matrilysin and macrophage metalloelastase (Fig. 7) ; previously matrilysin and macrophage metalloelastase have been detected in macrophages (Shapiro et al., 1993; Busiek et al., 1995) but not in T cells. Matrilysin and macrophage metalloelastase may be used by inflammatory cells to penetrate the interstitial tissue spaces; this suggestion is supported by Busiek et al. (1995) , who reported that in vivo matrilysin was localized to macrophages only in areas of severe, ongoing inflammation, and Shipley et al. (1996) demonstrated that macrophages of macrophage metalloelastase-deficient mice had a markedly diminished capacity to invade basement membranes. In addition, both matrilysin and macrophage metalloelastase have potent and broad-spectrum proteolytic activity against extracellular substrates (Shapiro et al., 1993; Wilson and Matrisian, 1996) . In the later stages of EAN, foamy phagocytic macrophages remained positive for matrilysin and macrophage metalloelastase, showing the same MMP profile as a group of lipid-laden macrophages in atherosclerotic lesions (Halpert et al., 1996) . Therefore, these two MMPs could be selectively regulated by phagocytosis of lipid debris and be actively involved in the degradation of myelin components.
Stromelysin-1 in EAN
Early during EAN the expression of stromelysin-1 is similar to that of 92 kDa gelatinase. Stromelysin-1 mRNA levels are elevated above those of controls and the immunoreactivity around endoneurial blood vessels is increased. Stromelysin-1 can also be implicated in the disruption of the blood-nerve barrier. Its expression, which is upregulated at peak disease severity, could equally be implicated in the destructive processes suggested for 92 kDa gelatinase, macrophage metalloelastase and matrilysin. In addition, it may be involved in controlling the amount of proteolytic damage to the nerve, as it is capable of activating the proforms of both 92 kDa gelatinase (Okada et al., 1992) and matrilysin in vitro (Imai et al., 1995) .
In the later stages of EAN we detected axonal damage and Schwann cell proliferation in regions of prominent inflammation (data not shown). Early during Wallerian degeneration in the rat sciatic nerve we have found a sharp decrease in stromelysin-1 mRNA levels (data not shown). Wallerian degeneration may therefore contribute to the fall in stromelysin-1 mRNA expression seen during EAN (day 21). Schwann cells in control rat sciatic nerves were immunopositive for stromelysin-1 (Fig. 5D ). In culture, quiescent Schwann cells constitutively produce stromelysin-1, which has been proposed to exert an indirect negative influence on Schwann cell proliferation (Muir et al., 1990; Muir and Manthorpe, 1992) . It is possible that stromelysin-1 may be involved in a proteolytic pathway which regulates Schwann cell proliferation, and that following nerve injury Schwann cells downregulate stromelysin-1 mRNA before dividing.
Potential MMP substrates in EAN
Components of Schwann cells, and the myelin sheath which they form, have been implicated as targets of the inflammatory response in EAN (Kadlubowski and Hughes, 1979; Saida et al., 1981; Linington et al., 1992) . These potentially antigenic molecules are not normally exposed since they are usually concealed by the basal lamina and surrounding collagen cuff. Amongst the components of the basal lamina are collagen IV, fibronectin, laminin and proteoglycans (Bunge, 1993) , all of which are readily degraded by the MMPs. In EAN the MMPs produced by inflammatory cells, and Schwann cells themselves, could therefore be involved in the remodelling of the basal lamina, which may result in the exposure of autoantigens. There are no studies which have investigated the effect of the inflammatory response on the basal lamina during EAN, but in Wallerian degeneration the Schwann cell basal lamina remains relatively intact structurally (Thomas, 1964) , although early ultrastructural changes have been reported (Giannini and Dyck, 1990) . A recent study suggested that, despite elevated levels of 92 kDa gelatinase during Wallerian degeneration, the basal lamina was not degraded because of an increase in TIMP-1, the endogenous inhibitor of MMPs (La Fleur et al., 1996) . We have not studied the level of TIMPs during EAN, but the number of MMPs which show upregulated expression and the effect of BB-1101 in attenuating disease severity when given from symptom onset (Redford et al., 1997) suggest excessive MMP activity which could result from an imbalance between MMPs and TIMPs. Work is in progress to study the specific involvement of the TIMP family during immune-mediated diseases of the PNS.
TNF-α in EAN
We have confirmed the findings of others Wagner and Myers, 1996) that TNF-α is constitutively expressed in Schwann cells in the rat PNS, and that during EAN the expression levels of TNF-α are elevated and localized to infiltrating macrophages; in addition TNF-α immunoreactivity associated with endoneurial blood vessels was increased (Figs 3E and 8) . TNF-α has been implicated in the pathogenesis of EAN , but exactly how TNF-α exerts its effects in the PNS is not known. MMPs, including matrilysin, stromelysin-1 and 92 kDa gelatinase, are able to cleave the membrane-anchored precursor of TNF-α to its mature, active form in vitro, and MMP inhibitors prevent the cellular processing of pro-TNF-α in vivo (Gearing et al., 1994) . Two recent reports suggested that the TNF converting enzyme may be a new member of the mammalian adamalysin family (Black et al., 1997; Moss et al., 1997) . It seems likely, however, that under pathological conditions where local levels of MMPs are high, they could contribute to the release of cell surface TNF-α. Conversely, TNF-α has been shown to upregulate MMP expression in macrophages (Saren et al., 1996) and endothelial cells (Hanemaaijer et al., 1993) . Disruption of the blood-brain barrier following intracerebral infusion of TNF-α was dependent on increased expression of 92 kDa gelatinase (Rosenberg et al., 1995) , and microinjection of TNF-α into the rat PNS primarily affected the vasculature, resulting in the focal accumulation of inflammatory cells in the vessel walls (Redford et al., 1995) . It is therefore possible that TNF-α mediates some of its pathogenic effects on nervous tissue through the induction of MMPs.
MMP activity in tissues
Zymography showed an increase in the activated forms of stromelysin-1 and matrilysin during EAN (Fig. 9) . Although zymography allowed detection of both the proform and the activated form of the MMPs, the results should be interpreted cautiously for the following reasons. The electrophoretic process efficiently separates the MMPs from their endogenous inhibitors, the TIMPs. Whether these MMPs are active in the tissue cannot be determined, as a stoichiometric excess of TIMPs would abate the effect of MMPs even if the enzymes were in their active form. Zymography itself could activate the proform of the MMPs (Kleiner et al., 1994) , although this would be expected to happen to a similar extent in control and experimental samples. Homogenization of tissue could artificially activate enzymes or permit contact of enzymes localized in distinct compartments in the intact tissues, which may degrade active MMPs. This possibility was reduced by addition of a broad range of proteinase inhibitors, including specific MMP inhibitors.
Summary and conclusion
In summary, we have identified five MMPs which are expressed at significant levels in the sciatic nerves of naive and control rats, including 72 kDa gelatinase, MT-MMP1, MT-MMP2, stromelysin-1 and stromelysin-3, and we have profiled MMP expression during the development of EAN. The profiles of 92 kDa gelatinase and stromelysin-1 mRNA and their cellular localization suggest that these enzymes may participate in the breakdown of the blood-nerve barrier. In EAN the most significant change in MMP expression was that of matrilysin, consistent with its substantial upregulation during experimental autoimmune encephalomyelitis (Clements et al., 1997) . This is strong circumstantial evidence that matrilysin could be particularly important in the pathogenesis of acute neuroinflammatory diseases. Macrophage metalloelastase showed similar patterns of expression and cellular distribution to matrilysin, hence it is possible that both these enzymes are involved in leukocyte extravasation and disruption of the myelin sheath. Overall this work has indicated that MMPs probably play a multifactorial role in the pathogenesis of EAN, suggesting that there may be several different stages at which MMP inhibitors could prove therapeutically useful in acute inflammatory diseases of the PNS. critical review of the manuscript. This work was supported by British Biotech Pharmaceuticals Ltd, the Medical Research Council (grant G94 16298N), the British Biotechnology Science and Research Council (BBSRC) and the Multiple Sclerosis Society of Great Britain and Northern Ireland (to K.J.S.). P.M.H. is a BBSRC industrial CASE student.
